Podcasts about tirzepatide

In this episode of the Flex Diet Podcast, I sit down with my good friend John Gorman to unpack the current “wild west” of peptides, TRT, GLP medications, and performance-driven bloodwork. We dig into how John's telemedicine clinic approaches comprehensive lab testing — and why running a full panel (including markers like reverse T3) matters far more than cherry-picking a few numbers. If you've been dieting hard, training consistently, and still feeling stuck, we break down how chronic stress, poor recovery, and subtle hormone disruptions can quietly crush metabolism and make fat loss feel like a white-knuckle grind. We also cover testosterone replacement therapy (TRT) — the real pros and cons, common oversimplifications in the industry, and what most clinics fail to discuss. From there, we dive into GLP-1 medications and tirzepatide, what we currently know, what we don't know about long-term use, and how to think critically about risk versus reward. John shares practical guidance on legitimate peptide sourcing, red flags to watch for, and how to think about “periphery” tools like methylene blue and injectable carnitine without getting sucked into hype. If you're interested in optimizing performance, improving body composition, or simply making smarter decisions in a rapidly changing medical landscape, this episode will help you separate signal from noise. Sponsors: Daily Fitness Insider Newsletter: https://flex-diet.kit.com/bfa1510fa8 Available now: Grab a copy of the Triphasic Training II book I co-wrote with Cal Deitz here. Episode Chapters: 03:20 Johns Telemed Launch 05:15 How Lab Consults Work 08:23 Coaches and Bloodwork Ethics 13:25 Reverse T3 Explained 16:56 Stress Hormones and Dieting 20:08 Microdosing Tirzepatide 26:30 Long Term GLP1 Concerns 30:45 TRT Done Right 33:10 Better Clinics Better Consumers 35:56 Vetting Coaches and Clinics 37:40 Peptides Wild West 38:50 Spotting Bunk Peptides 41:22 Legit Sources and Protocols 42:30 Evidence vs Hype 45:17 How to Verify Quality 50:54 Which Peptides Matter 54:14 Methylene Blue and Carnitine 57:50 Dosing and Safety Notes 01:02:06 Wrap Up and Recommendations 01:04:03 Music Picks and Outro 01:07:07 Final Disclaimers  Flex Diet Podcasts you may enjoy: Episode 319: Exploring the World of Peptides with Anthony Castore YouTube: https://www.youtube.com/watch?v=RbTY6kRP1H4&t=11s Episode 212: The Pros and Cons of Training Elite Level Professional Athletes: An Interview with Dr. Andy Galpin YouTube: https://www.youtube.com/watch?v=rf1imcUu-Ew Connect with John: Instagram: https://www.instagram.com/team_gorman YoulTube: https://www.youtube.com/@TeamGormanPhysiqueEnhancement Get In Touch with Dr Mike: Instagram: Drmiketnelson YouTube: @flexdietcert Email: Miketnelson.com/contact-us

The State of Hormone & Peptide Industry with Phil Vela Disrupting the health & wellness industry. (2:15) "It's that hard to do IT, so it's that easy to succeed once you've done IT." (2:48) What he did before he started Vita Bella, and the origins of the company. (5:00) The most applicable skills gained from his previous career. (7:41) Calling out the 'Grey Market' and its competition. (9:44) The state of the peptide industry and the fallout with Transcend. (15:54) Results & service. (25:23) Breaking down the Vita Bella membership package. (30:07) Businessman at heart. (33:34) Why he believes it should be illegal to prescribe GLP-1s by themselves. (35:13) Bad actors giving bad guidance. (43:33) His outlook for the future of the industry. (45:14) Will Ozempic and Tirzepatide ultimately bankrupt the United States? (53:27) The importance and value of having a trainer while on a GLP-1. (56:47) "I didn't build this business for money. I built it for a legacy!" (59:07) "Newer" peptides that have been impressed by. (1:03:16) Rapid fire: The best peptide for… (1:11:56) Related Links/Products Mentioned Visit Vita Bella for an exclusive offer for Mind Pump listeners! ** The first 50 signups will get a Vita Bella welcome box. You can finally achieve a top 1% all-around health at an affordable price! ** Get 20% off Kion at getkion.com/mindpump ** No code needed automatically applied at check out! ** MAPS Great 8 Launch - (Retail $127, Code: LAUNCH for 50% off!) ** Launch bonus include: MAPS GREAT 8 Nutrition Guide. ** Visit: http://mapsgreat8.com/  Mind Pump Store Mind Pump Hormones Facebook Private Forum GLP-1 Litigation: Compounder Sues Eli Lilly, Novo Nordisk Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Federal Court Tosses Lilly's Suit Against Strive Pharmacy: Jurisdiction Still Matters Mind Pump #2125: Heal Like Wolverine: BPC 157 with Dr. William Seeds Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Phil Vella – "Philly" (@phillyvz) Instagram Jay Campbell (@jaycampbell333) Instagram Rick Niemi (@gods.economy) Instagram Dr. William Seeds (@williamseedsmd) Instagram Peter Attia, M.D. (@peterattiamd) Instagram    

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden sits down in person with fitness and nutrition expert Autumn Calabrese to unpack the full truth about GLP-1 agonists. With millions of people jumping on semaglutide, tirzepatide, and soon retatrutide, the conversation most doctors aren't having is about what's actually happening inside the body while the scale goes down. Dr. Gladden breaks down how GLP-1s suppress hunger, slow metabolism, and trigger muscle wasting when used without proper diagnostics or a supporting protocol. He explains the critical differences between GLP-1s, GLP-2s, and GLP-3s, reveals why the ghrelin rebound causes most people to regain everything they lost, and shares the strategies he uses in his practice to help patients lose fat while protecting lean tissue. From the 5-day fasting mimicking diet to natural GLP-1 boosters like metabolic probiotics and calocurb, this episode lays out a smarter, more sustainable path to optimizing body composition. Whether you're considering a GLP-1, already on one, or looking for alternatives, this is the conversation that could change your entire approach. For Audience • Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!  • Subscribe to the Gladden Longevity Newsletter for the latest on longevity medicine, peptide protocols, and hormone optimization → https://start.gladdenlongevity.com/subscribe • Ready to find out what's really going on inside your body? Book a call with the Gladden Longevity team → https://start.gladdenlongevity.com/apply-now Takeaways • Peptides are signaling partners, not substitutes for the work your body needs to do.  • GLP-1s were designed for diabetics and metabolic syndrome, not casual weight loss. • GLP-1s decrease energy expenditure while GLP-3s (retatrutide) increase it. • Many GLP-1 users are losing muscle mass instead of fat without realizing it. • The ghrelin rebound after stopping a GLP-1 drives appetite higher than before while metabolism stays slower. • A fasting blood sugar and hemoglobin A1C alone are not enough to understand your metabolic health. • A two-hour glucose tolerance test with an insulin curve reveals insulin resistance most doctors completely miss. • The 5-day fasting mimicking diet resets ghrelin, taste buds, gut biome, and leptin sensitivity without destroying muscle. • You can boost your body's own natural GLP-1 production through the right probiotics and bitter receptor activation. • Weight gain is not always an appetite problem. Thyroid dysfunction, declining sex hormones, and missing micronutrients can all be the real driver. • Sex hormone optimization during perimenopause and andropause is critical for maintaining body composition. • Willpower never wins long term. Systems and environment design are what create durable results.    Chapters 00:00 Introduction and Welcome with Autumn 00:44 What Is a Peptide and How Peptides Work in the Body 03:07 BPC-157 and the Pharma Model vs. Peptide Signaling 05:00 You Can't Out-Peptide Bad Habits 06:31 What Is a GLP-1 and How It Affects Your Brain and Gut 08:57 GLP-1s Were Designed for Diabetics Not Weight Loss 09:40 GLP-2 Tirzepatide and GLP-3 Retatrutide Explained 11:00 Why Retatrutide Increases Energy Expenditure While GLP-1s Decrease It 12:00 The Muscle Mass Crisis on GLP-1s 14:06 The Patient Who Lost 20 Pounds of Pure Muscle 15:00 Protecting Muscle with Perfect Aminos and Creatine 17:00 Autumn's Personal Supplement Stack for Training 19:00 Food Noise Ghrelin and the Appetite Rebound 21:18 The 5-Day Fasting Mimicking Diet as a Metabolic Reset 23:00 Building Your Own Natural GLP-1 Production 25:00 The Glucose Tolerance Test Most Doctors Never Run 28:30 Risks of GLP-1s Pancreatitis Thyroid Tumors and Unsupervised Use 29:50 Microdosing GLP-1s in Perimenopause 30:30 Calocurb the Natural Appetite Suppressant from Hops 32:00 Sex Hormone Optimization for Body Composition 35:00 Resting Metabolic Rate Testing and Hidden Thyroid Dysfunction 38:00 Autumn's Hormone Health Program and Real Results 39:30 Willpower vs Systems and Architecting Your Environment 41:30 Bio-Individuality and Why Someone Else's Plan Won't Work for You 43:00 The Power of Diagnostics and Understanding Your Genetics  To learn more about Autumn: Instagram: @autumncalabrese Reach out to us at: Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw   Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode, we discuss:In high-risk individuals, an unhealthy lifestyle, including smoking, significantly increases progression to advanced age-related macular degeneration.In older Asian adults, undiagnosed age-related eye diseases were common and associated with worse vision, quality of life, and higher healthcare costs.Tirzepatide was linked to lower risks of developing POAG, OHTN, and needing glaucoma treatment compared with selective GLP-1 receptor agonists.Gut microbiome changes were linked to retinitis pigmentosa, with antibiotics slowing degeneration in a mouse model.

Send a textThis episode unpacks Novo's aggressive price cuts, Lilly's head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo's plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo's pricing move may blunt Lilly's trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo's early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo's Triple to RetatrutideAnalysis of weight loss percentages versus Lilly's retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

In this episode, Gianna Beasley interviews Aja Beckett, the founder of Shotsy, a companion app for individuals on GLP-1 medications. Aja shares her personal journey with obesity and the challenges she faced before discovering GLP-1s. We dive into the struggles of weight management, the creation of the Shotsy app, its features, and the importance of community support. Shotsy is a mobile health tracking app specifically designed for people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Semaglutide, and Tirzepatide. It helps users monitor their injection schedule, side effects, and progress toward goals like weight loss or health improvements. Aja discusses the app's freemium model, ensuring accessibility for all users, and discusses the significance of building trust within the GLP-1 community.Download Shotsy in the App Store on Apple or Android!

I've been sick all week, and it completely disrupted my plans, my workouts, and the momentum I thought I was building.In this episode, I'm talking about what it feels like when your body forces you to rest — and why we often only “allow” ourselves to slow down when we're physically unwell. If you're feeling behind, off track, or like you have to start over, this is your reminder: you're not starting over. You're continuing.Show Notes!

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast. The Points of CARE, the official podcast of Diabetes, Obesity, and Cardiometabolic CARE, will highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. In this special inaugural episode, host Richard Beaser, MD also discusses the ADA's Obesity Association and the "Standards of Care in Overweight and Obesity." 4:15 Beaser speaks with Alissa Segal, PharmD, RPh, CDCES, CDTC, FCCP. Dr. Segal is editor in chief of Diabetes, Obesity, and Cardiometabolic CARE and professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences. Her editorial, "Diabetes, Obesity, and Cardiometabolic CARE: Building New From a Strong Foundation," is available for free at doi.org/10.2337/doci25-0010. 13:00 Samar Hafida, MBCCh, joins the conversation. Dr. Hafida is a board-certified endocrinologist and weight management specialist at Boston Medical Center and assistant professor of medicine (Endocrinology, Diabetes, Nutrition & Weight Management) at the Boston University Chobanian & Avedisian School of Medicine. She is also vice president of the ADA's Obesity Association. Her editorial, "Introducing the Obesity Association and the Launch of Our Official Journal," is available for free at doi.org/10.2337/doci25-0012. 17:55 Dr. Hafida discusses "Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity." This article is available for free at doi.org/10.2337/doci25-0008. 20:05 Richard and Alissa highlight a few articles from the first issue of Diabetes, Obesity, and Cardiometabolic CARE. Simpkins et al. "Association of Type 2 Diabetes Subgroups With Incident Peripheral Neuropathy" doi.org/10.2337/doc25-0051 Livingston et al. "The Benefits and Costs of Treating Obesity Among Adults in the Medicaid Program" doi.org/10.2337/doci25-0005. Davidson et al. "Effectiveness of Using Patient-Defined Meal Sizes to Determine Bolus Doses of Insulin" doi.org/10.2337/doc25-0018 Ali et al. "Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity" doi.org/10.2337/doc25-0026 Masiano et al. "Type 2 Diabetes Treatment and Experience With Hospitalization in Older Adults: A Convergent Mixed-Methods Study" doi.org/10.2337/doc25-0009 Young et al. "The Critical Role of Diabetology Pharmacists in Improving Cardiovascular-Kidney-Metabolic Care and Outcome" doi.org/10.2337/doc25-0049 To learn more about Diabetes, Obesity, and Cardiometabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February 11, these GLP-1 drugs, including semaglutide in Ozempic and tirzepatide in Mounjaro, lead to average weight losses of 11 to 16 percent over one to two years in people with obesity, far outperforming placebos in trials with thousands of participants. Tirzepatide achieved about 16 percent reduction after 12 to 18 months, while semaglutide hit roughly 11 percent after 24 to 68 weeks, with benefits lasting as long as treatment continues. However, most studies were funded by drugmakers, long-term safety data remain limited, and common side effects like nausea affect many users.A Rutgers Health study published this week in the Journal of Medical Internet Research, as reported by Healthline on February 16, reveals that Ozempic users often prioritize weight loss over these side effects. Researchers analyzed online reviews and found that 67 percent reported reduced appetite and cravings alongside weight loss, making them satisfied enough to continue despite gastrointestinal issues in 62 percent of cases. Lead author Abanoub Armanious noted that everyday users value efficacy highly, even tolerating discomfort that prompts some to stop other treatments. Bariatric surgeon Mir Ali added that patients paying out of pocket show strong motivation, often seeking remedies for nausea rather than quitting.Novo Nordisk announced on February 17 that a new clinical study demonstrated people lost about 21 percent of their body weight on average with their obesity treatment, highlighting ongoing advancements in GLP-1 therapies. No fresh comments from Oprah Winfrey on Ozempic emerged this week, though her past support underscores the cultural buzz around these medications.Experts like Juan Franco from Heinrich Heine University emphasize the excitement after decades without effective options, but call for independent long-term studies on heart health, quality of life, and weight regain after stopping. Access issues persist due to high costs, though semaglutide patents expire this year, potentially lowering prices.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Part 2 picks up right where Part 1 ends—and goes deeper into what people are really wondering: What's safe? What's real? And who can I trust? Jamie and Jaclyn  talk about how misinformation spreads, why some people experience negative outcomes (often by skipping proper dosing, labs, and provider follow-ups), and why these wellness tools are most powerful when used with structure and medical guidance. You'll also hear a transformation story that's bigger than weight—one that changed energy, marriage, medications, and an entire family's trajectory. This episode is a reminder that the first step isn't dramatic… it's brave. www.YourHealth.Org

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic from medical breakthroughs to real-life health impacts.Recent Cochrane reviews commissioned by the World Health Organization show that Ozempic, or semaglutide, leads to about eleven percent average weight loss after six to eighteen months in people with obesity, outperforming placebo in eighteen trials with nearly twenty-eight thousand participants. Tirzepatide, like Mounjaro, achieves even more at sixteen percent, while liraglutide offers four to five percent. These glucagon-like peptide-one drugs mimic a hormone that slows digestion and boosts fullness, originally for type two diabetes but now key for weight management with diet and exercise.Cochrane researchers note benefits persist during treatment but highlight gaps: most trials were industry-funded, long-term safety data is limited, and side effects like nausea affect many, with some dropping out. No clear edge on heart events or death versus placebo yet.A Rutgers Health study in the Journal of Medical Internet Research analyzed sixty online reviews and found sixty-seven percent of users report weight loss, less appetite, or fewer cravings, making them stick with it despite nausea or vomiting in sixty-two percent. Lead author Abanoub Armanious says everyday experiences show benefits often outweigh gut issues for motivated users. Bariatric expert Mir Ali adds diarrhea or pain prompts more quits than nausea.Newer buzz includes Ozempic face: rapid fat loss causes gaunt cheeks, per a Gujranwala Medical College analysis and American Academy of Facial Plastic and Reconstructive Surgery survey, boosting filler demand by fifty percent. Weight regain post-treatment is common, stressing lifestyle pairing.Wegovy now offers semaglutide pills like Rybelsus, matching injections for seventeen percent loss with changes, per Prisma Health's Eva Wolf.Listeners, blend these tools with habits for lasting wins. Thanks for tuning in—subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Hear from the co-editors-in-chief of Osteoarthritis and Cartilage journal on what they thought were the latest advances in osteoarthritis research in 2025.Anne-Marie Malfait, MD, PhD, is Professor of Medicine and the Klaus E. Kuettner, Chair of Osteoarthritis Research at Rush University. She is co-Editor-in-Chief of Osteoarthritis and Cartilage journal alongside David Hunter.RESOURCESDavid's papers Comparative efficacy and safety of exercise modalities in knee osteoarthritis: systematic review and network meta-analysis Clinical and cost-effectiveness of a cycling and education intervention versus usual physiotherapy care for the treatment of hip osteoarthritis in the UK (CLEAT): a pragmatic, randomised, controlled trial The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and ObesityAnne-Marie's paperFM-dye inhibition of Piezo2 relieves mechanically evoked pain in mouse models of acute inflammatory and osteoarthritic knee painAssociation of Synovial Innate Immune Exhaustion With Worse Pain in Knee OsteoarthritisLipidomics unravels lipid changes in osteoarthritis articular cartilageCONNECT WITH USJoin one of our trials https://www.osteoarthritisresearch.com.au/current-trialsInstagram: @ProfDavidHunterTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news and updates on Ozempic, from its medical uses to its effects on lifestyle and health.Ozempic, containing semaglutide, mimics a natural hormone called GLP-1 to release insulin, steady blood sugar, slow digestion, and curb appetite, helping listeners feel full longer. GoodRx reports that studies show people on Ozempic lose six to seven percent of body weight, while Wegovy users average fifteen percent.Recent Cochrane reviews commissioned by the World Health Organization, released February eleventh, twenty twenty-six, confirm GLP-1 drugs like Ozempic deliver meaningful weight loss. Semaglutide leads to about eleven percent reduction after six to seventeen months, with benefits lasting up to two years if continued. Tirzepatide in Mounjaro and Zepbound shows even higher losses around sixteen percent, though more research is needed. Liraglutide offers four to five percent loss.Real-world evidence from Applied Clinical Trials highlights heterogeneous results, typically four to twelve percent loss at six to twelve months. For a twelve percent drop, the drug accounts for sixty-three percent, with context like persistence, lifestyle, and care making up thirty-seven percent. Improving persistence could boost outcomes further.Many hit an Ozempic plateau after twelve months, per GoodRx. Factors include dose, timing, diet, exercise, stress, and other meds like sulfonylureas or antidepressants. Pair it with avoiding fried foods, high-fat items, sugary drinks, and ultra-processed foods for best results.Rutgers Health research in the Journal of Medical Internet Research finds sixty-seven percent of users report weight loss or less appetite despite side effects like nausea, prioritizing effectiveness to keep going. However, stopping leads to regain, though half maintain some loss after a year.Watch for Ozempic face, gauntness from facial fat loss, as noted in a PMC study, so discuss screening and diet with doctors.These updates show Ozempic transforms lives when combined with healthy habits, but long-term independent data is key.Thank you listeners for tuning in. Subscribe for more insights. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commissioned by the World Health Organization analyzed GLP-1 drugs including semaglutide, sold as Ozempic and Wegovy. These studies, drawing from dozens of trials with tens of thousands of participants, show semaglutide leads to an average weight loss of about 11 percent after six to 18 months when paired with diet and exercise. Tirzepatide, marketed as Mounjaro and Zepbound, achieved around 16 percent loss in similar periods. Researchers note these benefits persist during treatment but emphasize limited long-term safety data, common side effects like nausea, and heavy industry funding in most trials. Cochrane reports highlight the need for independent studies on heart health, quality of life, and global access, as high costs limit use in lower-income regions.A Rutgers Health study published this week in the Journal of Medical Internet Research examined why Ozempic users stick with it despite side effects. Analyzing online reviews, researchers found perceived effectiveness in curbing appetite and shedding pounds outweighs issues like stomach upset for most. Lead author Abanoub Armanious noted that everyday users prioritize real results over hype from celebrities or social media. Separately, Weill Cornell Medicine researchers reported on February 11 that GLP-1 drugs like tirzepatide may lower risks of diabetic retinopathy progression in diabetes patients, countering earlier concerns.Oprah Winfrey continues to speak openly about her GLP-1 use, as covered in recent AOL articles. The media icon, who lost about 50 pounds starting in 2023 but regained 20 after briefly stopping, now views these medications as a lifelong tool like blood pressure drugs. Promoting her book Enough, Winfrey shared on The View and her podcast that the drugs silenced constant food thoughts, freeing her from self-blame. She told listeners obesity is not a willpower failure but a brain-driven condition, urging others to seek medical options without shame. Winfrey, who covers costs for friends, also noted reduced alcohol cravings as a bonus.Meanwhile, excitement builds around Eli Lillys oral pill orforglipron, an injectable-free alternative to Ozempic. Phase 3 trials like ATTAIN-1 showed 12.4 percent average weight loss over 72 weeks, with many maintaining results after switching from shots. Walk In reports it could launch in Canada soon, offering daily convenience without fasting, though generics of semaglutide arrive mid-2026 for affordability.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Lately, the world is heavy. Overwhelming. At times, even unsafe. And I'll be honest, it's been hard to show up and talk about things like body image, weight, or self-care when everything around us feels so serious.But then I watched the Super Bowl halftime show and Bad Bunny showing up boldly, joyfully, unapologetically, and it brought me back to a quote that stopped me in my tracks: joy is part of the resistance.In this episode, I'm sharing a very real moment of burnout. One where I was so overwhelmed I would've rather gone to the emergency room than keep dealing with life, even though nothing was physically wrong. We talk about the kind of society we're living in, where people secretly wish for a stomach virus just to get a break, and what it means when rest only feels allowed through sickness.I share why a glow up has shifted from nice-to-have to need-to-have — focusing first on the inside, not the outside — and how choosing movement, care, joy, and self-respect isn't avoidance, it's survival.If you feel exhausted, overwhelmed, and weighed down by the world around you, this episode is for you.

Send a textThis week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly's earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next. Clear context, real-world implications, and what patients should be discussing with their doctors right now.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

If you hit menopause and suddenly feel like your metabolism has slammedon the brakes, you're not alone—and you're not failing! In this episode, we unpack why weight gain after menopause is so stubborn and why “eat less, move more” often stops working altogether!We dive into the emerging science behind hormone replacement therapy (HRT) and tirzepatide, a next-generation GLP-1/GIP medication, and how they may work together to address the hormonal and metabolic shifts driving midlife weight gain. We also explore where thyroid health fits into the picture—and why ignoring it can sabotage your results.This is a must-listen for anyone curious about smarter, more personalized approaches to weight loss after menopause. Expect evidence-based insights, clear explanations, and empowering takeaways to help you decide what options actually make sense for your body—now and moving forward.

Ozempic promete hacerte perder peso rápido.Pero casi nadie te explica qué le está pasando realmente a tu cuerpo mientras lo usas.Hoy te explico qué dice la ciencia de verdad sobre Ozempic, Wegovy y Mounjaro: cómo funcionan, qué efectos tienen realmente, qué riesgos existen, cuándo NO deberías usarlos y por qué perder peso rápido no siempre significa mejorar tu salud.En este vídeo aprenderás:• Qué es Ozempic y cómo actúa en tu cerebro y tu apetito• Cuánto peso se pierde realmente según los estudios• Efectos secundarios frecuentes: náuseas, vómitos, problemas digestivos• Riesgo de pérdida de masa muscular (y por qué eso empeora tu metabolismo)• Problemas de vesícula y pérdida rápida de peso• Advertencia sobre tumores tiroideos observados en animales• Cuándo NUNCA deberías usarlo• En qué casos médicos extremos podría tener sentido• Y la alternativa real: hábitos que funcionan sin depender de fármacosSi estás pensando en usar Ozempic para adelgazar, mira este vídeo antes de tomar una decisión.Si te gusta el contenido claro, basado en ciencia, suscríbete al canal y activa la campanita.Déjame en comentarios tu opinión: ¿usarías Ozempic o prefieres cambiar hábitos?

In this episode, I sit down with one of my former mentors and professors, Dr. Alan Penzias, Medical Director at Boston IVF and Associate Professor at Harvard Medical School, to discuss his recent editorial in the Annals of Internal Medicine titled "The Weighty Issue of Obesity and Reproductive Success."  Read the full show notes on Dr. Aimee's website.  We dive deep into how age and weight factor into the fertility equation and why these conversations are so critical for anyone trying to conceive. Dr. Penzias shares his decades of experience helping patients navigate the complex intersection of body mass index, maternal age, and reproductive success, offering practical guidance on when to seek treatment and how to optimize your health before trying to get pregnant. In this episode, we cover: How age remains the strongest predictor of fertility success and why both partners should consider timing The U-shaped curve of BMI and fertility: why both low and high body mass index can impact conception Practical strategies for doctors for discussing weight and fertility with patients in a shame-free, empowering way When to prioritize immediate fertility treatment versus taking time for weight optimization based on age The role of GLP-1 medications (like Tirzepatide) in fertility treatment and safe protocols for use Why unexplained infertility may have hidden explanations related to weight and metabolic health The "do the as if" philosophy: building sustainable health habits one step at a time Resources: Dr. Alan Penzias and Boston IVF: BostonIVF.com Dr. Penzias's editorial: "The Weighty Issue of Obesity and Reproductive Success" - Annals of Internal Medicine https://www.acpjournals.org/doi/10.7326/ANNALS-25-02742  Dr. Penzias's YouTube video: "Evidence-Based Approach to Unexplained Infertility" https://youtu.be/9j4lNvmaXts?si=zmMFZFOno0sWnhcn  American Society for Reproductive Medicine (ASRM) Practice Committee resources on overweight and fertility https://www.asrm.org/ Dr. Stephanie Fein  - Fertility Weight Loss Specialist: https://www.stephaniefeinmd.com/  Hillary Wright, Nutritionist at Boston IVF: https://www.bostonivf.com/physicians/hillary-wright Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, February 9, 2026 at 4pm PST, where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom.   Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org. Other ways to connect with Dr. Aimee and The Egg Whisperer Show: Subscribe to my YouTube channel for more fertility tips!Subscribe to the newsletter to get updates  

In this episode, we sit down with Terri Ross, founder of Terri Ross Consulting, healthcare business strategist, and former Fortune 500 executive, for a deep, practical conversation on how health coaches and wellness entrepreneurs can build scalable, profitable businesses — even in competitive markets. Terri brings over 20 years of experience in medical devices, aesthetics, sales psychology, and healthcare consulting. She's worked across oncology, cardiology, endocrinology, dermatology, plastic surgery, med spas, and integrative wellness — and now helps cash-based practices dramatically improve revenue, efficiency, and client results. This episode is a must-listen for health coaches, wellness professionals, med spa owners, and clinicians who want to stop underpricing, stop trading time for dollars, and start building businesses that actually scale.

Oprah Winfrey has been candid this week about her ongoing use of GLP-1 medications like those containing semaglutide, the active ingredient in Ozempic, for weight management. In recent interviews promoting her new book Enough: Your Health, Your Weight, and What It's Like to be Free, co-authored with Yale professor Dr. Ania M. Jastreboff, she shared that she started these weekly injections in 2023 and views them as a lifelong tool, much like blood pressure medicine. Oprah told People magazine she feels no shame in relying on them, explaining that after stopping for six months to test her willpower, she regained 20 pounds despite strict dieting and exercise. She now believes obesity influences overeating through genetics and hormones, freeing her from self-blame after decades of public scrutiny and jokes about her weight.Social media buzzed with debate over her comments on The View, where she said obesity causes overeating rather than the reverse, a view some experts clarify starts with overeating leading to obesity, which then complicates appetite control via elevated hunger hormones. Still, Oprah emphasizes these drugs help by reducing hunger and slowing stomach emptying, as noted by Harvard Health.Meanwhile, regulators issued fresh guidance on GLP-1s this week. The UK's Medicines and Healthcare products Regulatory Agency updated advice for prescribers and patients on semaglutide products like Ozempic and Wegovy, highlighting a small risk of severe acute pancreatitis. They noted about 1.6 million adults in England, Wales, and Scotland used these for weight loss between early 2024 and early 2025, per University College London research. In Canada, generic semaglutide became possible after Novo Nordisk's data exclusivity expired on January 4, promising more affordable options soon.Long-term data reinforces their efficacy. The STEP 5 trial showed once-weekly semaglutide yielding 15.2 percent sustained weight loss at 104 weeks, with mild gastrointestinal side effects like nausea most common. Tirzepatide, a dual agonist, outperformed in the SURMOUNT trials with up to 25 percent loss over 88 weeks. Experts like Dr. Caroline Apovian from Harvard stress indefinite use for best results, alongside diet and exercise, while new oral versions and pipeline drugs like amycretin aim to improve access.Thanks for tuning in, listeners. Come back next week for more. Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

If you've started a GLP-1 medication and found yourself thinking, "Why am I so tired all of a sudden?", you're definitely not alone. Today, we're talking specifically about fatigue with semaglutide and tirzepatide—what the research actually shows, why fatigue seems more common with some GLP-1s than others, and what you can do if your energy feels lower than usual. Read the Full Episode Transcript: https://pepties.com/fatigue-on-semaglutide-or-tirzepatide/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Purchase Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

Could medications originally designed for diabetes actually help treat addiction, eating disorders, and the biology of cravings?In this part 2 of 2-part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to dig deeper into the science, myths, and emerging uses of GLP-1 agonists. Dr. Wharton explains that these medications don't simply reduce appetite, they calm what he calls “food noise,” the constant mental pull toward eating that many people with obesity experience. This neurological effect has opened the door to exciting possibilities: early research suggests GLP-1 drugs may also reduce cravings for alcohol and other addictive behaviors.  Dr. Wharton also clarifies the confusing world of brand names. Ozempic and Wegovy are both semaglutide; Mounjaro and Zepbound are tirzepatide. The differences are largely about FDA indications and insurance coverage, not completely different medications.The episode tackles common fears patients and clinicians hear every day. Do these medications cause eating disorders? No, in fact, they may help treat them. Are the side effects dangerous? Usually not, and most are manageable with proper dosing. Is “Ozempic face” real? It's simply normal fat loss, not a drug-specific problem. Most importantly, Dr. Wharton reinforces a compassionate, evidence-based message: obesity is a chronic, biological disease, and GLP-1 medications are tools to treat it, just like medications for blood pressure or diabetes.Three Actionable TakeawaysGLP-1 Medications Affect the Brain as Much as the Stomach: These drugs reduce “food noise” and cravings, helping patients regain control over eating behaviors. Their impact is neurological, not simply about willpower or restriction.Side Effects Are Real—but Usually Manageable: Nausea, constipation, and GI symptoms are the most common issues, especially early on. Starting low and increasing doses slowly makes treatment far more tolerable.Treatment Decisions Should Be Individualized:  Not every patient must stay on these medications forever. Conversations about duration, goals, and expectations should be collaborative and tailored to each person.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textCan Zepbound treat PCOS? That's the question this clinical trial will seek to answer, and we cover it exclusively on this week's On The Pen podcast.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Watch Here : https://www.youtube.com/watch?v=S8M-kPa-0UI Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

This episode covers: • Real Food Reset in U.S. Dietary Policy The new Dietary Guidelines for Americans 2025–2030 put real food back at the center of U.S. nutrition policy and take a direct swing at ultra processed foods, added sugar, and sugary drinks. Dave breaks down why this matters beyond personal dieting: these guidelines influence school meals, SNAP and WIC, federal feeding programs, and they shape what eventually shows up on labels and in public institutions. He also shares how biohackers can use this shift as leverage to push for better food environments in schools, workplaces, and hospitals. -Source: https://www.usda.gov/about-usda/news/press-releases/2026/01/07/kennedy-rollins-unveil-historic-reset-us-nutrition-policy-put-real-food-back-center-health • Drug Combo Extends Lifespan of Frail Old Mice by 73% A new aging study found that combining oxytocin with a compound called A5i extended the remaining lifespan of frail elderly male mice by 73%, while also improving function and tissue health. Dave explains why this is a big signal for the future of longevity medicine: stacking targeted interventions can outperform single compounds, especially when you start late in life. He also explains what to do with the idea right now: stop building random “everything stacks” and start thinking in phases, tracking outcomes, and waiting for real human combo data. -Source: https://www.futura-sciences.com/en/study-finds-drug-combo-could-slow-aging-and-increase-lifespan-by-73_23229/ • ChatGPT Health Turns Your Data Into a Health OS OpenAI launched ChatGPT Health, a dedicated health experience that lets you securely connect medical records and wellness apps like Apple Health and MyFitnessPal, so you can summarize visits, interpret labs, and prepare better questions for your doctor. Dave explains why this is a turning point for quantified self and protocol building: it reduces the friction of pulling data from five different places, and it makes pattern-finding accessible to nontechnical people. He also shares how to use it like a pro: clean inputs, smarter questions, and better doctor conversations. -Source: https://openai.com/index/introducing-chatgpt-health/ • Whole Milk Is Back in Schools The Whole Milk for Healthy Kids Act restores whole and reduced-fat milk options in schools, aligning school nutrition rules with the updated dietary guidelines that no longer treat full-fat dairy like a default villain. Dave breaks down why this matters for child healthspan: satiety and nutrient density drive behavior, learning, and metabolic stability. He also explains why this is a real-world policy experiment worth watching across school districts, and how it can open the door for bigger institutional upgrades like better protein and fewer ultra processed items. -Source: https://www.usda.gov/about-usda/news/press-releases/2026/01/14/whole-milk-back-president-trump-signs-whole-milk-healthy-kids-act • Tirzepatide Trial Targets Biological Age With Aging Clocks A registered clinical trial titled Tirzepatide to Slow Biological Aging is using multiple DNA methylation aging clocks as primary endpoints, along with functional metrics like grip strength and a 6-minute walk test. Dave explains why this is a big maturity step for longevity science: instead of assuming metabolic improvement equals slower aging, this study is measuring biological age directly, across multiple clocks, with performance outcomes. He also shares the practical lesson for biohackers: stop relying on one favorite metric and start thinking in panels, function, and durability of results. -Source: https://clinicaltrials.gov/study/NCT07220473 All source links provided for direct access to the original research and reporting. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want practical strategies rooted in cutting-edge science. Host Dave Asprey translates emerging research into actionable upgrades for your biology, from metabolism and food policy to AI-driven tracking, institutional nutrition, and biological aging measurement. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: Dietary Guidelines for Americans 2025-2030, real food policy reset, ultra processed foods policy, added sugar limits, sugary drinks guidelines, school lunch nutrition policy, SNAP WIC nutrition impact, USDA HHS dietary guidelines 2026, whole food protein guidelines, full fat dairy guidelines, oxytocin aging study, A5i lifespan extension, frail elderly mice lifespan 73 percent, combination longevity therapies, aging intervention synergy, staged longevity protocols, functional aging biomarkers, ChatGPT Health launch, OpenAI health records AI, Apple Health ChatGPT integration, MyFitnessPal ChatGPT integration, AI lab interpretation, AI doctor visit summary, quantified self AI tools, Whole Milk for Healthy Kids Act, whole milk back in schools, school dairy policy change, child satiety nutrition, school meal regulations USDA, tirzepatide biological aging trial, GLP-1 GIP longevity, epigenetic aging clocks trial, DNAmAge PhenoAge GrimAge DunedinPACE, grip strength aging endpoint, 6 minute walk aging endpoint, biological age measurement, longevity clinical trial endpoints, biohacking news update, longevity policy shifts, metabolic health upgrades Thank you to our sponsors! -BEYOND Conference 2026 | Register now at https://beyondconference.com/ -EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE for 40% off Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps:0:00 - Intro0:19 - New Dietary Guidelines2:09 - Longevity Research Breakthrough3:41 - ChatGPT Health Launch5:10 - Whole Milk Returns to Schools6:29 - GLP-1 Aging Trial7:34 - Weekly Upgrade Protocol9:09 - OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Mark, Kate, Henry and Gary as they discuss 4 new POEMs (Patient Oriented Evidence that Matters, studies with the potential to change practice): a summary of the evidence on tirzepatide (Zepbound) for weight loss, using the Beers list with your patients, high vs standard dose flu vaccine and the risk of hospitalization, and whether stent or endarterectomy are better than maximal medical therapy for patients with asymptomatic carotid stensosis. Here are the links:Essential Evidence Plus: www.essentialevidenceplus.comTirzepatide systematic review: https://pubmed.ncbi.nlm.nih.gov/41015578/ Tirzepatide vs dulaglutide: https://pubmed.ncbi.nlm.nih.gov/41406444/Applying the Beers list: https://pubmed.ncbi.nlm.nih.gov/40697073/ High vs standard dose flu vaccine: https://pubmed.ncbi.nlm.nih.gov/41115437/ Another high dose flu trial: https://pubmed.ncbi.nlm.nih.gov/39230284/ Asymptomatic carotid stenosis treatment: https://pubmed.ncbi.nlm.nih.gov/41269206/

Most people think they go into your body and make all new tissue… but in actuality, they are a delivery mechanism of growth factors. I call them the ultimate traffic cop. In this episode, the host converses with Dr. Jesse Morse, a physician specializing in regenerative and anti-aging medicine. They delve into the intricacies of stem cells and their various sources, including bone marrow, fat, and donor tissue.  Dr. Morse highlights the role of exosomes and growth factors in the healing process. The discussion also focuses on the prevention and treatment of Achilles tendon tears, emphasizing the importance of blood supply, proper diagnosis, and innovative therapies. Additionally, they explore the benefits and applications of various peptides, including BPC 157, TB 500, and MotC, for enhancing healing, anti-aging, and overall health. Dr. Morse also addresses the significance of nutrition and detoxification in maintaining optimal health and preventing injuries. Dr. Jesse Morse is a Miami-based, double board-certified physician in Family and Sports Medicine who specializes in regenerative medicine, injury recovery, and longevity. Since shifting from traditional sports medicine in 2020, he has focused on non-surgical approaches to tendon and ligament injuries using therapies like PRP, stem-cell–based treatments, exosomes, and peptides, alongside functional and anti-aging strategies centered on mitochondrial health, immune support, toxin reduction, and personalized recovery—helping everyone from active adults to high-performance athletes restore function and prevent major injuries like Achilles tears while educating widely online. Connect with him on: Instagram: https://www.instagram.com/drjessemorse/ — Sports medicine, regenerative medicine & insights Linktree (aggregated links to socials & resources): https://linktr.ee/DrJesseMorse   Supplements, Compounds & Peptides Collagen (protein / connective tissue support): https://www.ncbi.nlm.nih.gov/books/NBK507922/ Vitamin C (collagen activation / antioxidant): https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ Creatine (muscle & mitochondrial support): https://ods.od.nih.gov/factsheets/Creatine-HealthProfessional/ BPC-157 (peptide – tendon & gut healing): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504390/ TB-500 / Thymosin Beta-4 (peptide – tissue repair): https://pubmed.ncbi.nlm.nih.gov/22674782/ GHK-Cu (copper peptide – skin, joints, stem-cell signaling): https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu MOTS-c (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/25174616/ SS-31 / Elamipretide (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/29515116/ Thymosin Alpha-1 (immune modulation peptide): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367996/ LL-37 (antimicrobial / immune peptide): https://pubmed.ncbi.nlm.nih.gov/15184378/ 5-Amino-1MQ (NNMT inhibitor / fat loss): https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1MQ N-Acetylcysteine (NAC – liver & detox support): https://www.ncbi.nlm.nih.gov/books/NBK537183/ Glutathione (antioxidant / detox): https://ods.od.nih.gov/factsheets/Glutathione-HealthProfessional/ NAD⁺ / NMN / NR (mitochondrial & anti-aging support): NMN: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-mononucleotide NR: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-riboside Regenerative & Injection Therapies PRP – Platelet-Rich Plasma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990861/ Bone Marrow–Derived Stem Cells (BMAC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630382/ Adipose-Derived Stem Cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416130/ Amniotic / Placental Tissue Products: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124018/ Exosomes (cell signaling vesicles): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465611/ Ultrasound-Guided Injections: https://radiopaedia.org/articles/musculoskeletal-ultrasound-guided-injection Needle Tenotomy (scar-tissue disruption): https://pubmed.ncbi.nlm.nih.gov/30428129/ Detox, Blood & Environmental Interventions Sauna (heat detox & cardiovascular benefit): https://www.health.harvard.edu/staying-healthy/saunas-and-your-health Binders – Modified Citrus Pectin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452227/ GI Detox / Toxin Binders (general concept): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654245/ Heavy Metal Chelation (DMPS concept): https://pubmed.ncbi.nlm.nih.gov/12198644/ Mercury Toxicity: https://www.cdc.gov/mercury/index.html Microplastics in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068600/ EBOO Therapy (ozone-based blood filtration): https://pubmed.ncbi.nlm.nih.gov/36681461/ Therapeutic Plasma Exchange (TPE): https://www.ncbi.nlm.nih.gov/books/NBK557561/ INUSpheresis (advanced plasma filtration): https://pubmed.ncbi.nlm.nih.gov/37324197/ Medications & Drug Classes Mentioned Corticosteroids (Prednisone – tendon risk): https://medlineplus.gov/druginfo/meds/a601102.html Fluoroquinolone Antibiotics (tendon rupture risk): https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-fluoroquinolone-antibiotics GLP-1 Agonists (Semaglutide / Tirzepatide / Retatrutide discussion): Semaglutide: https://pubmed.ncbi.nlm.nih.gov/36421543/ Tirzepatide: https://pubmed.ncbi.nlm.nih.gov/35220624/ Nutrition & Food-Related Mentions Protein Intake & Muscle Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566799/ American Gluten vs European Wheat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799814/ Seed Oils & Inflammation (discussion topic): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196963/ Dairy & Inflammation (contextual mention): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122229/ Key Mechanisms & Concepts Poor Blood Supply in Achilles Tendon (Watershed Zone): https://pubmed.ncbi.nlm.nih.gov/17021202/ Mitochondrial Dysfunction & Aging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843959/ Stem Cells as "Medicinal Signaling Cells": https://pubmed.ncbi.nlm.nih.gov/25784997/   Show Notes 00:00 Introduction to Exosomes and Stem Cells 01:01 Dr. Morse's Background and Transition to Regenerative Medicine 02:03 Achilles Tendon Tears: Causes and Prevention 05:02 Preventative Measures and Treatments for Achilles Injuries 10:26 The Role of Nutrition in Tendon Health 12:53 Peptides and Their Impact on Tendon Health 15:50 Stem Cells: Misconceptions and Applications 20:52 Comparing Stem Cell Sources and Their Potency 29:52 The Controversy of International Stem Cell Treatments 34:04 Cleaning Toxins from Your Blood 34:19 The Toxic Burden in Our Environment 35:57 Practical Detox Methods 37:47 Mercury and Heavy Metal Testing 44:47 The Problem with American Gluten 46:49 Underrated Peptides for Health 53:42 Growth Hormone and Anti-Aging 01:03:34 Advanced Blood Cleaning Techniques 01:04:51 Conclusion and Contact Information   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

I recently read something that stopped me in my tracks: being fat robbed me of my femininity.And I haven't been able to shake it.In this episode, I pose a question that came out of a Reddit thread but really speaks to a shared experience so many of us quietly lived: growing up, did femininity ever feel like it wasn't meant for you?I'm sharing my own experiences of being invisible next to friends, being talked about like I wasn't even a person, not being able to shop where other girls shopped, missing out on certain “girlhood” moments, and learning very early on which bodies were allowed to be soft, desired, and feminine and which weren't.We'll talk about how those moments shape us long after childhood, how confidence can coexist with old wounds, and what it actually looks like to take your femininity back without performing it or earning permission.If you've ever felt like girlhood passed you by, or like femininity came with conditions you didn't meet, this episode is for you. You're not alone—and you didn't imagine it.Show Notes!

In this episode, I'm sharing my real-life “vacation ready body” routine and the things that help me feel confident heading into a trip, especially when swimsuits are involved.I'm talking about what I'm finally doing differently for myself: my GLP-1 journey (specifically tirzepatide), how it's supported my insulin sensitivity, and the mindset shift that's come with choosing a new kind of care for my body. Plus, I'm breaking down my go-to glow up staples before I travel: my favorite Sun Tan City spray tan (yes, I always do double legs), the workouts I actually stick with: HOTWORX, walking with my weighted vest, and my Peloton Tread routine.Buy Me A Coffee: https://buymeacoffee.com/kelseygravesFollow me on Instagram: https://www.instagram.com/kelsey_gravesFollow me on TikTok: https://www.tiktok.com/@mskelseygravesJoin us in the Trip Tales Podcast Community Facebook Group: https://www.facebook.com/groups/1323687329158879Mentioned in this episode:- Tiffany Balin, NP (https://www.instagram.com/tiffanybalin_np) with Salus Integrative (https://www.salusintegrative.health/)- Insulin Sensitivity and Hypoglycemia- GLP-1s: Tirzepatide and Semaglutide- Sun Tan City Spray Tan: Catalina tint, dark, double legs- HOTWORX- Weighted vest walks- Peloton Tread- Laser Hair Removal- Mel Robbins quote

Dr. Centor discusses the comparative risk for severe gastrointestinal adverse events associated with dulaglutide, semaglutide, and tirzepatide with Dr. Wajd Alkabbani.

Welcome to Ozempic Weightloss Unlocked, the podcast where we dive into the latest developments surrounding weight loss medications and their real-world impact on your health and lifestyle.I'm your host, and today we're exploring some fascinating new research that shows just how complex the weight loss medication story really is.Let's start with what we know works. According to recent clinical studies, medications like semaglutide, sold as Ozempic and Wegovy, can help people lose around fifteen percent of their body weight. Tirzepatide, known as Mounjaro and Zepbound, has shown even more impressive results, reaching up to twenty percent weight loss in some cases. These are significant numbers that have genuinely changed lives for millions of people.But here's what's been making headlines lately. A major study from Cornell University just revealed something eye-opening about how these medications are reshaping American spending habits. Within six months of starting these drugs, households cut their grocery spending by over five percent. Fast food spending dropped even more dramatically, by about eight percent. The biggest declines appeared in ultra-processed snacks and sweets, which fell by roughly ten percent.Now, let's talk about what happens when people stop taking these medications. And this is important for our listeners to understand. Research published in the British Medical Journal found that people regain weight incredibly quickly after stopping. Those on newer drugs like semaglutide and tirzepatide regain about two pounds per month, returning to their starting weight in roughly one and a half years. Compare that to traditional diet and exercise programs, where weight regain happens at about one quarter pound per month, taking nearly four years to return to baseline.The metabolic benefits fade too. According to recent research, improvements in blood sugar, cholesterol, and blood pressure levels return to their original measurements within about one point four years after stopping medication.Let's address the side effects, because listeners deserve to know the full picture. Most people taking these medications experience nausea, vomiting, and diarrhea. More serious complications can include muscle loss, pancreatitis, and gallbladder issues. When people stop these drugs, they often experience weight regain that can trigger anxiety and depression.There's also a crucial perspective from leading medical experts. According to Francesco Rubino, Chair of Metabolic and Bariatric Surgery at King's College London, not all weight loss is necessary for everyone. His recent research suggests that obesity shouldn't be treated as a uniform disease. Instead, doctors should ask whether a person's weight is actually causing them harm right now. If someone's extra weight isn't affecting their health or organ function, it may not warrant aggressive intervention.This reframes an important conversation. Weight loss medications work best when they're part of a comprehensive approach that includes behavioral changes, nutritional guidance, and ongoing medical care. They're most effective when combined with lifestyle modifications, not as standalone solutions.The mental and emotional toll matters too. Many people blame themselves when their weight loss plateaus or when they regain weight after stopping medication. It's crucial to understand that biology, not willpower or morality, determines these outcomes.As we continue to navigate this new era of weight loss medications, remember that the goal should always be improved health and wellbeing, not simply a number on the scale.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you never miss an episode as we continue tracking this evolving story.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Today we're diving into how medications like semaglutide, tirzepatide, and retatrutide work in the body—and how they compare to the hormones your body naturally produces. Once you understand the biology behind them, their effects start to make a lot more sense. Read the Full Episode Transcript: https://pepties.com/the-science-behind-semaglutide-tirzepatide-and-retatrutide/ Dr. Nikki's Qualifications: https://bifat.life/about/ Related Links/Products Mentioned: Peptide Podcast Partners Page https://pepties.com/partners/ Purchase Peptides online at BioLongevity Labs: Use our link and enter COUPON CODE: PEPTIDEPODCAST  at checkout to receive 15% off your total order:  https://go.biolongevitylabs.com/SH5C Momentous Supplements (we use Creatine, Vital Aminos, Whey Protein) https://crrnt.app/MOME/OqGQOxGA LMNT – More Salt, Not Less.  https://elementallabs.refr.cc/default/u/johnjavit Thorne Supplements (we use Omega-3 with CoQ10, Red Yeast Rice, Zinc) https://get.aspr.app/SH1KvW Organifi Creatine and Shilajit Gummies http://rwrd.io/rlbkajm?c MitoZen (methylene blue for Cognitive Function, Anti-Aging, Mental Clarity) https://www.mitozen.com/ref/cnlwiztypt/ For skin and hair health (Copper Tripeptide-1)  Visit Luminose by Entera for an exclusive offer for Peptide Podcast listeners!  ** Promo code PEPTIDEPODCAST at checkout for 10% off an order or 10% off the first month of a subscribe-and-save. ** https://www.enteraskincare.com/?rfsn=8906839.f93c72 NAD+ Push Patch: https://www.pushpatch.com/

If you're a midlife woman who feels like you're doing everything right — lifting weights, eating well, walking, managing stress — and your body still isn't responding, this episode is for you.In this powerful, myth-busting conversation, I'm joined by Dr. Rocio Salas-Whalen, a triple board-certified endocrinologist, obesity medicine specialist, author, and early adopter of GLP-1 therapies in the U.S. Dr. Salas-Whalen helps us understand why weight gain in midlife is not a willpower problem — it's a biology problem.We break down:Why midlife metabolism changes so dramatically during perimenopause and menopauseHow GLP-1 medications actually work (in plain English)Why muscle is the true organ of longevity — and how to protect it while using GLP-1sThe truth about side effects like hair loss, nausea, and “Ozempic face”Microdosing vs. full dosing, long-term use, and what's coming next in obesity medicineWhy shame-based weight loss advice is outdated — and harmfulWe also talk about Dr. Salas-Whalen's new book, Weightless, a science-backed, compassionate guide to GLP-1 medications and metabolic health that validates what so many women have experienced for decades. You can find Weightless wherever books are sold.This episode is about options, not pressure. Facts, not fear. And building health for the long game.Instagram https://www.instagram.com/drsalaswhalen/Website https://www.nyendocrinology.com/_________________________________________1:1 health and nutrition coaching or Faster Way - Reach me anytime at mailto:mfolanfasterway@gmail.com If you're doing “all the right things” and still feel stuck, it may be time to look deeper. I've partnered with EllieMD, a trusted telehealth platform offering modern solutions for women in midlife—including micro-dosed GLP-1 peptide therapy—to support metabolic health and longevity. https://elliemd.com/michelefolan - Create a free account to view all products. ✨ Sign up for my weekly newsletter: https://michelefolanfasterway.myflodesk.com/i6i44jw4fq

This week, primary care physicians Kate Rowland, Mark Ebell, Gary Ferenchick and Henry Barry tackle 4 new practice changing studies (POEMs): bathing frequency for people with eczema, tirzepatide in obese children and adolescents with T2DM, a new flu vaccine, and whether beta-blockers still matter after MI.

Midlife weight gain, burnout, and metabolic changes often get mislabeled as willpower issues. This episode challenges the oversimplified weight loss narrative and unpacks why many women feel blindsided by changes even when their habits stay solid.We dive deeper into this in the Broads episode with Dr. Tyna Moore. We also chat about why GLP-1 was never meant to be a vanity weight loss tool, why microdosing doesn't mean what most people think it means, and the real risks of frailty and why strength equals long-term freedom.Dr. Tyna Moore is a Licensed Naturopathic Physician and Chiropractor with over 30 years in the medical field, specializing in holistic regenerative and metabolic medicine. She earned her degrees from the National College of Natural Medicine and the University of Western States Chiropractic College. Dr. Tyna is also the host of The Dr. Tyna Show and an international speaker.What's Discussed:(08:48) How being “early” to the GLP-1 conversation led to backlash and burnout(10:49) How GLP-1 became misused and distorted by telemedicine and influencers(15:18) Why midlife weight gain isn't about willpower but a neurological shift(16:09) The idea of functional deficiency and why modern stress breaks signaling(19:15) How GLP-1 can increase motivation to move through brain plasticity(22:20) How GLP-1 can magnify existing hormonal deficiencies in women(24:11) Why movement is essential for gut health and metabolic signaling(28:01) Why microdosing is not a true weight loss strategy(35:44) Why strength training is non-negotiable for women in midlife(39:02) The real risks of frailty, hip fractures, and loss of independenceCheck out more from Broads:Website: www.broads.appInstagram: @broads.podcast @broads.appCheck out more from Tara LaFerrara:Website: www.taralaferrara.comInstagram: @taralaferraraYoutube: @TaraLaferraraTiktok: @taralaferraraCheck out more from Dr. Tyna, ND, DC:Website: www.drtyna.comInstagram: @drtynaYoutube: @drtyna

This issue will review: 1.     Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 2.     SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 3.     Continuous SGLT-2, GLIP-1RA and Frailty Progression in Older Adults with Type 2 Diabetes   4.     Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 5.     Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial 6.     Listening to Hypoglycemia: Voice as a Biomarker for Detection of a Medical Emergency Using Machine Learning Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

A large cardiovascular outcomes trial in high-risk adults with type 2 diabetes showed that a dual incretin therapy was noninferior to an established comparator for major adverse cardiovascular events over four years, with similar overall safety but more gastrointestinal side effects and no added cardiovascular benefit. Separate trials demonstrated that a single-bolus thrombolytic was as effective and safe as standard infusion therapy for acute ischemic stroke while simplifying workflows, and that vascular brain injury and inherited risk independently increase dementia risk, underscoring the importance of aggressive management of modifiable vascular factors.

Broadcast from KSQD, Santa Cruz on 12-18-2025: Dr. Dawn opens by examining how market competition is actually working in the weight loss drug sector. Novo Nordisk's Ozempic and Wegovy compete against Eli Lilly's Monjaro and ZepBound, with prices dropping nearly 50% as companies launch direct-to-consumer websites. The main barriers remain needles and refrigeration, driving development of oral versions. Novo's Wegovy pill awaits FDA approval for early 2026 launch at $150 monthly. Next-generation drugs show remarkable results: Eli's retatrutide causes 24% weight loss in 48 weeks, while Novo's Cagrisema combines semaglutide with amylin to reduce muscle loss. Pfizer paid $10 billion for Metsera's once-monthly drug despite significant side effects. A quick fiber tip suggests adding plain psyllium to morning coffee for cardiovascular and microbiome benefits. Start with half a teaspoon and work up to two teaspoons (10 grams) over several weeks to avoid gas. The prebiotic fiber improves glucose tolerance and may reduce cancer risk. UC San Diego scientists discovered why cancers mutate so rapidly despite being eukaryotic cells with protected chromosomes. The answer is chromothripsis, a catastrophic event where the enzyme N4BP2 literally explodes chromosomes into fragments. These reassemble incorrectly, generating dozens to hundreds of mutations simultaneously and creating circular DNA fragments carrying cancer-promoting genes. One in four cancers show evidence of this mechanism, with all osteosarcomas and many brain cancers displaying it. This explains why the most aggressive cancers resist treatment. Research from 2013 shows any glucocorticoid use significantly increases venous thromboembolism risk, with threefold increases during the first month of use. The risk applies to new and recurrent clots, affecting both oral and inhaled steroids, though IV poses highest risk and topical the lowest. Joint injections fall somewhere between inhaled and oral. Anyone with prior blood clots should avoid steroids except for life-threatening situations like severe asthma attacks requiring ventilation. A meta-analysis of 20 randomized controlled trials shows creatine supplementation helps older adults (48-84) maintain muscle mass when combined with weight training two to three times weekly. The supplement provides no benefit without exercise. Recommended dosing starts at 2 grams and works up to 5 grams daily. Vegans benefit most since they consume little meat or fish. Important caveat: creatine throws off standard kidney function tests (creatinine), so users should request cystatin C testing instead for accurate renal health assessment. A new JAMA study suggesting risk-based mammogram screening is fatally flawed. First, researchers offered chemopreventative drugs like tamoxifen only to the high-risk group, contaminating the study design. Second, the demographics skewed heavily toward white college-educated women, missing the reality that Black women face twice the risk of aggressive breast cancer with 40% higher mortality. Third, wild-type humans failed to follow instructions—low-risk women continued getting annual mammograms anyway while high-risk women skipped recommended extra screenings. The conclusion of "non-inferior" outcomes is meaningless given poor adherence. Stick with annual mammograms, and consider alternating with MRIs for high-risk women. The EAT-Lancet report condemns red meat based purely on observational data showing correlations with heart disease, cancer, and mortality. But people who eat lots of red meat differ dramatically from low consumers: they weigh more, smoke more, exercise less, and eat less fiber. Studies can't control for sleep quality, depression, or screen time. Notably, heavy meat eaters also die more in accidents, suggesting a risk-taking lifestyle phenotype. The inflammatory marker TMAO is higher in meat eaters, but starch is also pro-inflammatory. Eating red meat instead of instant ramen might improve health. A balanced diet with limited amounts beats epidemiology-based blanket statements. Dr. Dawn grades Dr. Oz's performance as CMS administrator. Starting at minus one for zero relevant experience, he earns plus two for promoting diet, exercise, and gut health on his show. He studied intensively after nomination, calling all four previous CMS directors repeatedly and surrounding himself with experienced staff (plus one). He finalized Medicare rules favoring prevention over surgery and earned bipartisan praise as "a real scientist, not radical" (plus one). He divested healthcare holdings but kept some blind trust interests (minus 0.5). He's developing a CMS app and partnering with Google on a digital health ecosystem (plus one), but supports ending ACA subsidies that will raise premiums for millions (minus one). He correctly promoted COVID vaccines and contradicted Trump's Tylenol-autism claims (plus one). Final score: 3.5 out of 5 possible points, the only positive score for any Trump health administrator.

Send us a textWelcome back Rounds Table Listeners! In our year-end episode, Drs. Mike and John Fralick discuss five important research studies published in 2025:Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO) (0:00 – 4:20)Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) (4:21 – 9:30)Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) (9:31 – 15:03)Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial (FRESH-UP) (15:04 – 18:09)Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) (18:10 – 23:49)The Good Stuff (23:50 – 25:27):Toronto Star Santa Claus Fund, Calgary Food Bank, The War Amps Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dawson Weiss Guest Episode on The Steroids Podcast Dan and Bodybuilder Dawson Weiss discussed various aspects of bodybuilding, including the effects of different compounds like Retatrutide and Tirzepatide on body composition and performance. Dawson Weiss shared his personal experiences with competing in bodybuilding shows and transitioning between different steroid cycles, while also discussing his current approach to training and diet. They explored the evolution of bodybuilding aesthetics and the challenges of maintaining a competitive mindset, with Dawson expressing his preference for a more natural and balanced physique rather than extreme measures.My Book: ULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING Link -⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bodybuilderinthailand.com/ultimate-guide-to-roids/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Daily Text Msg Training $99usd/month and 1 Hour Phone Call Consult $59usd Email to inquire about personal training to steroidspodcast@gmail.comBodybuilder in Thailand on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/bodybuilderinthailand/⁠⁠⁠⁠⁠⁠My Other Podcast: Grab the Bull Podcast: ⁠⁠⁠⁠⁠⁠https://youtu.be/X6SzfCrN4NY?si=Ho2T9WIVxLjXo_AE⁠⁠⁠Dawson Weiss on Instagramhttps://www.instagram.com/accounts/dawson_m_weissTimestamps: 0:00 Retatrutide Results and Thoughts after extended long term use.4:00 Thought of tirzepatide 8:15 Downsizing on the muscle fullness and freakiness a bit after first bodybuilding competition9:00 First Bodybuilding Competition Experience14:07 Being able to enjoy bodybuilding 15:58 Taking a break from HGH and Insulin20:20 Using testosterone and Deca NPP nandrolone now, current cycle26:00 Dawson seems to do well with high estrogen and progesterone and even takes tablets of Methyl Estradiol on cycle27:35 Bought a new house with his Fitness Influencer money30:45 Bodybuilding Food talking about current Diet36:00 Talking about Ronnie Coleman's legendary Mr Olympia Diet38:30 Discussion on Diuretics Use in Bodybuilding41:20 More Thoughts on Nandrolone, Primobolan and Trenbolone46:45 Bodybuilding Plans for 202649:40 Negative Cosmetic effects of Growth Hormone and Insulin58:04 Dorian Yates role in taking bodybuilding image from being having fun in the sun with girls, to this dark dungeon misery and maximum suffering sport.This Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

Chris Duffin sits down with Bizzie Gold, creator of the Break Method and author of "The Mind is a Filthy Liar," for a deep dive into the power of subconscious coding and emotional rewiring. If you've ever wondered why high achievers can succeed outwardly while struggling internally, or how to get unstuck from self-sabotaging patterns, this episode brings the answers. Bizzie Gold shares her unique, data-driven approach to identifying and breaking self-deceptive mental habits—going well beyond traditional therapy. She opens up about her own transformative journey, growing up in a household shaped by mental health challenges, and how a chance encounter with mushrooms and the movie Fight Club at 13 reshaped her worldview.

The cozy, magical season is here! Leggings, sweaters, cookies, hibernation mode. But this can also become the season where we disconnect from our bodies without even realizing it.In this episode, I'm sharing a truth we don't talk about enough:✨ The longer you hide in leggings and oversized sweatshirts, the longer you stay in denial about where you really are physically and emotionally. ✨ Getting dressed, putting on makeup, and wearing a real outfit isn't about vanity… it's about awareness, identity, and showing up for yourself. ✨ And what I don't want is for you to “wake up” in spring only to realize nothing fits and you don't recognize yourself.Let's talk about how you can stay connected, confident, and present with yourself even during cozy season so you don't lose yourself in the process.

Before we all slip into our cozy clothes and head toward the candied yams, I wanted to drop in with a quick Thanksgiving episode and a little love note from my heart to yours.Today, I'm sharing what I'm truly grateful for this season: you. Thank you for listening, for hanging with me through the messy seasons, the comebacks, the pauses, the growth, and all the moments in between. This community means more to me than I can ever put into words.I'm also talking about the real-life chaos of the holidays, the emotional weight many of us carry into this week, and some gentle reminders about food, body image, and giving yourself permission to just be you. You don't need to earn your Thanksgiving meal. You don't need to restrict. You don't need to go overboard. You're allowed to enjoy your plate, be present with your people, and let go of the guilt that diet culture tries to hand you.Take what you need, leave what you don't, and know that you're not alone.Wishing you a happy Thanksgiving filled with yummy food, core memories, and zero shame. I'm so grateful for you. 

The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬Sophia Ambruso @sophia-kidney.bsky.socialNayan Arora @captainchloride.bsky.socialSpecial Guests Brian Rifkin @brianrifkin.bsky.socialAnna Gaddy @AnnaGaddyEditing and Show Notes byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesBrian Rifkin and Cristina Popa ascend to co-editors in chief of NephJC.Paresh Jadav receives the first NephJC Champion award. Dr. Jadav hosted the NephJC night and saved NephJC thousands of dollars. It makes a huge difference in our fund raising. Thank you.Also a big thank-you to Jade Teakell for buying the cowboy hats!The first pick of the draft, by Sophia is Fish oil for dialysis: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (NEJM)The second pick, by Brian is FINE-ONE (Bayer Press release)Rajiv Agarwal's mediation analysis to show how much of finerenone's beneficial renal effects are captured by the reduction proteinuria: Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis (PubMed)Anna has the third pick and it goes to Katherine Tuttle and the REM0DEL Trial: REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide (Science Direct)Nayan goes off-board and picks a poster by a med student (backed by Testani)Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure (ClinicalTrials.gov)For the final pick in the draft Joel went with a little Lilly on Lilly violence: Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases (JASN)Bring out your dead…What's left on the draft board.Liberate-D A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial (JAMA)Atacicept for IgAN A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (NEJM)Lilia Cervantes crushed it with Community Health Worker Support for Hispanic and Latino Individuals Receiving Hemodialysis: The Navigate-Kidney Randomized Clinical Trial (JAMA)Tubular SecretionBrian: Late Breaking and High Impact Clinical Trials. Including Sibe! REGENCY Biopsy Data.Sophia: Flying Home. No, really it's the Electrolyte QuizJoel: The Poster Session, the Quiz Session, and Nayan: Flying to AHA to talk about dual-heart-kidney-transplantAnna: Kidney STARS! and Melanie Hoenig's session on potassium

In this powerful episode of The Determined Society, host Shawn French sits down with Jeffrey Delaney — founder of T Clinics and Nuviva Medical Weight Loss — to talk about what really happens when men lose their edge.Jeffrey breaks down the myths around testosterone, hormone therapy, nutrition, and popular GLP-1 medications like Ozempic and Tirzepatide. Together, he and Shawn unpack what it means to be a modern man — one who leads with strength, vulnerability, and consistency — while challenging the stigma around masculinity and self-care.If you've ever felt stuck, exhausted, or unsure how to get back to feeling like yourself again, this episode will show you where to start and how to take control of your health for good.Key Takeaways-True health isn't just physical — mental clarity begins in the body.-Hormone balance can reignite drive, motivation, and emotional stability.-Quick fixes like GLP-1s work only when paired with movement and nutrition.-Sleep, nutrition, training, and mindset are the four pillars of lasting wellness.-Masculinity isn't toxic — it's essential to family and personal balance.-Comparison kills progress; consistency creates transformation. Connect with me :https://link.me/theshawnfrench?fbclid=PAZXh0bgNhZW0CMTEAAaY2s9TipS1cPaEZZ9h692pnV-rlsO-lzvK6LSFGtkKZ53WvtCAYTKY7lmQ_aem_OY08g381oa759QqTr7iPGAJeffrey Delaneyhttps://linktr.ee/jeffreydelaney?utm_source=linktree_profile_share

GLP-1 weight loss drugs like Ozempic, Wegovy, and Tirzepatide are being promoted everywhere but what's missing is the full story. This episode breaks down the hidden GLP-1 side effects most women never hear about, from anxiety and dehydration to vision problems, muscle loss, and disordered eating risks. Chalene exposes how influencer affiliate programs and compounding pharmacies are fueling the hype while lawsuits and safety questions grow. You'll learn what informed consent should actually include, how to protect your metabolism, and why women over 40 need to question what's really behind this weight loss craze. Watch this episode on YouTube this Sunday!! 

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.